Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleNEUROPHARMACOLOGY

SSR180575 (7-Chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide), a Peripheral Benzodiazepine Receptor Ligand, Promotes Neuronal Survival and Repair

Badia Ferzaz, Emmanuel Brault, Genevieve Bourliaud, Jean-Pierre Robert, Gilles Poughon, Yves Claustre, Franck Marguet, Philippe Liere, Michael Schumacher, Jean-Pierre Nowicki, Jacqueline Fournier, Benoit Marabout, Mireille Sevrin, Pascal George, Philippe Soubrie, Jesus Benavides and Bernard Scatton
Journal of Pharmacology and Experimental Therapeutics June 2002, 301 (3) 1067-1078; DOI: https://doi.org/10.1124/jpet.301.3.1067
Badia Ferzaz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emmanuel Brault
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Genevieve Bourliaud
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Pierre Robert
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gilles Poughon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yves Claustre
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Franck Marguet
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philippe Liere
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Schumacher
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Pierre Nowicki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacqueline Fournier
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benoit Marabout
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mireille Sevrin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pascal George
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philippe Soubrie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jesus Benavides
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernard Scatton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

In the present study, we have investigated the potential neuroprotective effects of a novel peripheral benzodiazepine binding site (PBR) ligand, 7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide (SSR180575), in models of central and peripheral neurodegeneration in vivo and its effect on steroid concentrations in plasma and nervous tissue. SSR180575 shows high affinity (IC50, 2.5–3.5 nM) and selectivity for the rat and human PBR and potently inhibits the in vivo binding of [3H]alpidem to PBR in the rat brain and spleen after oral or i.p. administration (ID50, 0.1–0.3 mg/kg). In an experimental model of motoneuron degeneration induced by facial nerve axotomy in the immature rat, SSR180575 given i.p. or orally for 8 days rescued facial motoneurons, increasing their survival by 40 to 72% at 6 and 10 mg/kg p.o. b.i.d. Moreover, in this model, SSR180575 (10 mg/kg p.o. b.i.d.) increased by 87% the number of motoneurons immunoreactive to peripherin, a type III intermediate filament, whose expression is up-regulated during nerve regeneration. SSR180575 also improved functional recovery in acrylamide-induced neuropathy in the rat when given therapeutically at 2.5 to 10 mg/kg/day p.o. Furthermore, SSR180575 (3 mg/kg i.p. b.i.d.) accelerated functional recovery of the blink reflex after local injury of the facial nerve in the rat. SSR180575 increased pregnenolone accumulation in the brain and sciatic nerve (+100% at 3 mg/kg i.p.), suggesting that its neuroprotective effects are steroid-mediated. These results indicate that PBR ligands (e.g., SSR180575) promote neuronal survival and repair in axotomy and neuropathy models and have potential for the treatment of neurodegenerative diseases (e.g., peripheral neuropathies or amyotrophic lateral sclerosis).

Footnotes

  • Abbreviations:
    PBR
    peripheral benzodiazepine receptor
    TNFα
    tumor necrosis factor-α
    SSR180575
    7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide
    Ro5–4864
    4′chloro-diazepam
    PK11195
    1-(2-chlorophenyl)-N-methyl-N-(1-methyl-propyl)-3-isoquinoline carboxamide
    FK506
    tacrolimus
    PBS
    phosphate-buffered saline
    ANOVA
    analysis of variance
    AUC
    area under the curve
    HPLC
    high-performance liquid chromatography
    VDAC
    voltage-dependent anion channel
    CNTF
    ciliary neurotrophic factor
    LIF
    leukemia inhibitory factor
    • Received October 8, 2001.
    • Accepted February 4, 2002.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 301 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 301, Issue 3
1 Jun 2002
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
SSR180575 (7-Chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide), a Peripheral Benzodiazepine Receptor Ligand, Promotes Neuronal Survival and Repair
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleNEUROPHARMACOLOGY

SSR180575 (7-Chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide), a Peripheral Benzodiazepine Receptor Ligand, Promotes Neuronal Survival and Repair

Badia Ferzaz, Emmanuel Brault, Genevieve Bourliaud, Jean-Pierre Robert, Gilles Poughon, Yves Claustre, Franck Marguet, Philippe Liere, Michael Schumacher, Jean-Pierre Nowicki, Jacqueline Fournier, Benoit Marabout, Mireille Sevrin, Pascal George, Philippe Soubrie, Jesus Benavides and Bernard Scatton
Journal of Pharmacology and Experimental Therapeutics June 1, 2002, 301 (3) 1067-1078; DOI: https://doi.org/10.1124/jpet.301.3.1067

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleNEUROPHARMACOLOGY

SSR180575 (7-Chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide), a Peripheral Benzodiazepine Receptor Ligand, Promotes Neuronal Survival and Repair

Badia Ferzaz, Emmanuel Brault, Genevieve Bourliaud, Jean-Pierre Robert, Gilles Poughon, Yves Claustre, Franck Marguet, Philippe Liere, Michael Schumacher, Jean-Pierre Nowicki, Jacqueline Fournier, Benoit Marabout, Mireille Sevrin, Pascal George, Philippe Soubrie, Jesus Benavides and Bernard Scatton
Journal of Pharmacology and Experimental Therapeutics June 1, 2002, 301 (3) 1067-1078; DOI: https://doi.org/10.1124/jpet.301.3.1067
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • D1 agonist vs. methylphenidate on PFC working memory
  • Iclepertin (BI 425809) in schizophrenia-related models
  • Obesity Thwarts Preconditioning in TBI
Show more Neuropharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics